Ideenat 150mg Tablet

• Chronic lymphocytic leukemia (CLL),
• Follicular lymphoma (FL)
• Small lymphocytic lymphoma (SLL)

Ideenat 150mg tablet can cause serious side effects some are mild and some are severe. Patients may experience symptoms, however many of them are treated on their own and some need proper medical attention. Common ones include:

• Skin-peeling Mouth ulcer
• Ulcer in throat, nose, genital, and eye
• Skin rashes
• Fever
• DRESS syndrome (enlarged lymph nodes)
• Infections
• Liver damage
• Change in the number of WBC
• Increased liver enzymes
• Lung inflammation
• Reddish patch
• Changes in the skin color

Ideenat 150mg tablet should be taken under doctor prescription. The tablet should be taken with or without food at the same time everyday. Never skip or stop the medication without consultation with a doctor.  Regular follow ups and proper medical supervision attention are essential to ensure safe and effective treatment.

Ideenat 150mg tablet, a selective PI3K- delta inhibitor. It blocks signaling pathways responsible for the growth and survival of malignant B cells. This inhibition leads to reduced cell proliferation and induces programmed cell death. As, a result it helps control the cell progression of certain blood cancers like CLL and lymphomas.

• Gopal, A. K., Kahl, B. S., Flowers, C. R., Martin, P., Ansell, S. M., Abella-Dominicis, E., ... & Friedberg, J. W. (2017). Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood, The Journal of the American Society of Hematology, 129(22), 3037-3039. https://pubmed.ncbi.nlm.nih.gov/28325864/
• Weidner, A. S., Panarelli, N. C., Geyer, J. T., Bhavsar, E. B., Furman, R. R., Leonard, J. P., ... & Yantiss, R. K. (2015). Idelalisib-associated colitis: histologic findings in 14 patients. The American journal of surgical pathology, 39(12), 1661-1667. https://pubmed.ncbi.nlm.nih.gov/26448188/
• Gopal, A. K., Kahl, B. S., De Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., ... & Salles, G. A. (2014). PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. New England Journal of Medicine, 370(11), 1008-1018. https://pubmed.ncbi.nlm.nih.gov/24450858/
• Brown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., ... & Furman, R. R. (2014). Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology, 123(22), 3390-3397. https://pubmed.ncbi.nlm.nih.gov/24615777/
• Coutré, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., ... & Zelenetz, A. D. (2015). Management of adverse events associated with idelalisib treatment: expert panel opinion. Leukemia & lymphoma, 56(10), 2779-2786. https://pubmed.ncbi.nlm.nih.gov/25726955/